Sensome develops sensing technology that combines micro‑sensors with machine‑learning to instantly identify biological tissues upon contact and turn invasive medical tools into connected devices. The company’s first product is a guidewire called Clotild; with the new funding it will test Clotild’s clinical performance and prepare the product for market. Sensome was founded in 2014 as a spin‑off from CNRS and École Polytechnique and is based in France. The startup has partnered with Asahi Intecc on a two‑year development plan to design a new connected guidewire for ischemic stroke treatment. That collaboration includes integrating Sensome’s tissue sensor into Asahi’s Chikai guidewire to improve first‑try clot removal. The company raised Series B capital to fund clinical testing and product development. Sensome builds impedance-based micro-sensors combined with machine learning to instantly identify biological tissues, a capability the company says offers unequaled predictive reliability. The sensors are extremely thin and can be integrated into existing medical devices. Its first product, Clotild™, is a connected guidewire designed to determine clot content during ischemic stroke interventions to help physicians select optimal tools and reestablish blood flow. The company says Clotild™ targets faster, more informed stroke treatment and will undergo clinical testing. Sensome plans to bring Clotild™ to the European market and to explore additional applications of its sensing technology. Sensome recently completed a €4.6 million financing round to support these clinical and market efforts.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2020